ELTX Elicio Therapeutics Inc.
Price (delayed)
$6.01
Market cap
$95.88M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.25
Enterprise value
$103.12M
Highlights
ELTX's equity has dropped by 199% year-on-year but it is up by 40% since the previous quarter
The quick ratio has decreased by 46% QoQ but it has increased by 16% YoY
The net income has declined by 47% year-on-year and by 11% since the previous quarter
Key stats
What are the main financial stats of ELTX
Market
Valuations
Earnings
Shares outstanding
15.95M
Market cap
$95.88M
Enterprise value
$103.12M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$44.99M
Net income
-$51.9M
EBIT
-$51.44M
EBITDA
-$50.27M
Free cash flow
-$37.15M
Per share
Balance sheet
Liquidity
EPS
-$4.25
EPS diluted
-$4.25
Free cash flow per share
-$3.04
Book value per share
-$1.05
Revenue per share
$0
TBVPS
$2.31
Total assets
$28.18M
Total liabilities
$39.49M
Debt
$26.04M
Equity
-$11.31M
Working capital
$9.17M
Debt to equity
-2.3
Current ratio
1.8
Quick ratio
1.63
Net debt/EBITDA
-0.14
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-194.4%
Return on equity
N/A
Return on invested capital
-272.8%
Return on capital employed
-308.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ELTX stock price
How has the Elicio Therapeutics stock price performed over time
Intraday
9.27%
1 week
-22.85%
1 month
-26.53%
1 year
-20.08%
YTD
17.84%
QTD
-2.44%
Financial performance
How have Elicio Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$44.99M
Net income
-$51.9M
Gross margin
N/A
Net margin
N/A
The net income has declined by 47% year-on-year and by 11% since the previous quarter
The operating income has declined by 26% year-on-year and by 10% since the previous quarter
Growth
What is Elicio Therapeutics's growth rate over time
Valuation
What is Elicio Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Elicio Therapeutics's EPS has increased by 39% YoY but it has decreased by 25% from the previous quarter
ELTX's equity has dropped by 199% year-on-year but it is up by 40% since the previous quarter
Efficiency
How efficient is Elicio Therapeutics business performance
The company's return on assets has shrunk by 90% YoY and by 10% QoQ
ELTX's return on invested capital is up by 9% since the previous quarter and by 5% year-on-year
Dividends
What is ELTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ELTX.
Financial health
How did Elicio Therapeutics financials performed over time
The total assets is 29% smaller than the total liabilities
ELTX's total liabilities has soared by 150% YoY but it is down by 31% QoQ
The current ratio has contracted by 47% from the previous quarter but it has grown by 7% YoY
ELTX's equity has dropped by 199% year-on-year but it is up by 40% since the previous quarter
Elicio Therapeutics's debt to equity has plunged by 68% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.